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Abstract 
In the context of the global village, this paper focuses on the development of Non-Invasive 
Prenatal Testing (NIPT)—a test that provides clinicians and prospective parents with an easy, 
early and safe opportunity to obtain potentially reliable genetic and health information about 
the future child. 
In the first part of the article, we identify various concerns relating to NIPT, now released 
into an environment that is remarkably difficult to regulate. For example, we question 
whether the online information about NIPT upon which women might rely will be reliable 
and up-to-date, whether women might use Internet suppliers to work round local legal 
restrictions, and whether the stored test results might impact on future children. 
In the second part of the article, whilst recognising the limited opportunities for making 
effective regulatory interventions in the global village, we suggest some possible responses to 
the particular concerns about NIPT identified in the paper.   
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1. Introduction 
 
The development of Non-Invasive Prenatal Testing (NIPT)—a simple blood test administered 
about ten weeks into a pregnancy—has provided clinicians and parents with an easy, early, 
and safe opportunity to obtain largely reliable information about the baby.
1
  Although 
subsequent diagnostic tests may be required,
2
 for many women NIPT promises to reduce the 
need for, and occurrence of, invasive testing and the consequential risk of miscarriage.
3
  
While parents can already commission NIPT through the private sector—for example, 
Sequenom's MaterniT 21 PLUS test provides information on gender and for certain common 
and rare chromosomal abnormalities—the public health sector tends to lag behind, sometimes 
operating a contingent model where publicly funded testing is only offered as an option for 
certain risk groups.
4
 
If NIPT were being introduced in a highly regulated environment, rather than in the ‘global 
village’, it might be possible to assuage whatever concerns are prompted by the test. 
However, once NIPT, together with information about the test, is in circulation in the global 
village, we can make two assumptions (both of which are echoed by the Nuffield Council on 
Bioethics in a recent report on the ethics of NIPT).
5
 First, the Internet will play an important 
role in relation to pre-test decisions about the use of NIPT as well as post-test and post-birth 
decisions and outcomes.
6
 Secondly, making effective regulatory interventions in relation to 
NIPT services that are available online will be challenging.
7
  
In this paper, we start by assessing the opportunities, concerns and challenges that arise from 
the availability and use of NIPT—particularly concerning the reliability of online information 
about NIPT, the use of Internet suppliers to work round legal restrictions, and the impact on 
future children—and, then, we consider some possible domestic and global responses.  
                                                          
1
 For discussion, see Vardit Ravitsky, ‘Non-Invasive Prenatal Testing (NIPT): Identifying key clinical, ethical, 
social, legal and policy issues’ (commissioned by the Nuffield Council on Bioethics) 2015, available from 
http://nuffieldbioethics.org/wp-content/uploads/NIPT-background-paper-8-Nov-2015-FINAL.pdf (accessed 
22/02/17) at para 19. 
 
2
 This is the current position with chromosomal disorders: trisomy 21(Down’s syndrome), trisomy 18 (Edwards 
syndrome) and trisomy 12 (Patau syndrome).   
 
3
 R Akolekar et al., ‘Procedure-related Risk of Miscarriage following Amniocentesis and Chorionic Villus 
Sampling:  A Systematic Review and Meta-analysis’, (2014) 45(1) Ultrasound in Obstetrics and Gynecology 
16-26. 
 
4
 For example, the current (UK) NHS pilot offers NIPT following conventional screening tests (including serum 
screening and ultrasound) to high risk groups for trisomies 13, 18 and 21 (>1:150). 
 
5
  Nuffield Council on Bioethics, Non-invasive prenatal testing: ethical issues (London: Nuffield Council on 
Bioethics, 2017) (NCOB). 
 
6
 NCOB (n 5), at paras 2.31 (information about the test), 4.48 (NIPT and sex selection), and 4.54 (direct-to-
consumer services). 
 
7
 NCOB (n 5) para 4.48. 
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2. NIPT in the Global Village: Opportunities, Concerns and Challenges 
 
In this part of the paper we present some general remarks about the opportunities and 
challenges to which NIPT, in the context of the global village, gives rise, before considering 
questions and concerns that relate specifically to the pre-test, post-test, and post-birth phases. 
 
2.1 Opportunities and challenges 
 
On the face of it, the availability of NIPT (informing women about the status of their baby) in 
conjunction with the Internet (informing women about NIPT) is a significant advance. For 
those who advocate the facilitation of reproductive choice or who argue for a parental right to 
know specific genetic and developmental information about the unborn child, these new 
opportunities seem to be entirely for the good.  
 
Nevertheless, NIPT gives rise to various reservations and challenges—such as objections to 
the ‘medicalisation’ of pregnancy, the ‘commodification’ of life, the ‘trivialisation’ of  
abortion, and the like, Moreover, there are issues around the range and quality of the 
information that can and should be obtained, particularly if it involves analysis of the whole 
human genome;
8
 there is a concern that NIPT can generate uncertain and equivocal data as 
well as about the eugenic and normative implications of public health screening of particular 
disorders or conditions;
9
 and, of course, NIPT enhances parental choices only if the 
information presents lawful and transparent options.
10
   
 
Once NIPT is placed in the context of the Internet, further concerns and challenges emerge. 
For, while the Internet supports a range of services that might inform and educate parents 
about their reproductive options, as well as enabling the sharing of experiences with NIPT, it 
also provides a framework for laboratories and health service providers, whether for profit or 
not for profit, to promote the test. Moreover, patient access to online services can lead to 
problems for health professionals—for instance, where there is parental confusion, or 
unfounded expectations about the outcomes of prenatal testing; or where data is equivocal 
and creates difficult moral decisions for parents.
11
 
 
                                                          
8
 J O Kitzman et al., ‘Noninvasive Whole-genome Sequencing of a Human Foetus’, (2012) 4(137) Science 
Translational Medicine 137. 
 
9
 See for example, http://dontscreenusout.org/ (accessed 16/02/2017). See also NCOB (n5) at paras 5.18-5.19. 
 
10
  For discussion, see Jeffrey Wale, 'Don't forget the legal framework: the public provision of non-invasive 
prenatal testing in England & Wales', (2015) 4 Medical Law International 203-215. 
 
11
 See PK Agatisa et al., ‘A First Look at Women’s Perspectives on Non-invasive Prenatal Testing to Detect Sex 
Chromosome Aneuploidies and Microdeletion Syndromes’.(2015) 35(7) Prenatal Diagnosis 692-8(available at 
http://www.ncbi.nlm.nih.gov/pubmed/25800864). 
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2.2 Pre-test considerations 
If NIPT is to meaningfully inform reproductive choice, women need to have intelligible, 
reliable, balanced and accurate information about the test. However, there is no guarantee that 
information derived from a multiplicity of sources (both offline and online) will meet these 
standards; and, when women derive their information from Internet sources, the risks are all 
the greater.
12
 In the global village, how are trustworthy sources to be differentiated from the 
non-trustworthy?
13
  
Already, there is evidence—confirmed by the Nuffield Council on Bioethics’ own review14—
that online information about NIPT falls short. For instance, there is evidence that 
commercial test providers are pitching their online communications above the recommended 
reading age for public health information’,15  and that some commercial web advertising may 
contain inadequate or outdated information
16
 (the latter being a particular risk when 
technology advances so quickly).  Whilst the threat of deliberate miss-selling or fraud might 
be unlikely, it is no surprise that commercial test providers tend to emphasise the benefits 
rather than limitations of the technology in their marketing material.
17
  Links to peer 
reviewed citations are not always present and this can make it difficult to evaluate the nature 
and currency of the claims made.
18
  Further, private test providers do not always mention the 
specific abnormalities that can reliably be detected through conventional trimester 
screening,
19
 or the differentials in failure rates between different testing technologies.
20
   
 
 
                                                          
12
  See NCOB (n 5) at para 4.22 (for the Council’s own review of the adequacy of ‘information made available 
on the websites and in patient leaflets of manufacturers, hospitals and clinics’). 
 
13
 See NCOB (n 5) at paras 4.21-4.34 and 6.5-6.10. 
 
14
 See n 12. 
 
15
 MB Mercer, PK Agatisa and RM Farrell, ‘What patients are reading about non-invasive prenatal testing: an 
evaluation of Internet content and implications for patient-centered care’ (2014) 34(10) Prenat Diagn 986-93; 
JW Aarts et al., ‘Patient-focused internet interventions in reproductive medicine: a scoping review’ (2012) 18(2) 
Hum Reprod Update 211-27 at 212; and Heather Skirton et al.; ‘Non-invasive prenatal testing for aneuploidy: a 
systematic review of Internet advertising to potential users by commercial companies and private health 
providers’ (2015) 35(12) Prenat Diagn 1167-75. 
 
16
 Skirton (n 15); Mercer (n 15). 
 
17
 Skirton (n15) at 1174; Mercer (n 15). 
 
18
 The ARC website suggests that ‘to be of the highest quality, test performance data should be published in a 
peer reviewed scientific journal and should report pregnancy outcomes from studies involving 1000s of women.' 
Available from: http://www.arc-uk.org/tests-explained/non-invasive-prenatal-testing-nipt (accessed 16/02/17). 
 
19
 Mercer (n 15). 
 
20
 Yuval Yaron, ‘The implications of non-invasive prenatal testing failures: a review of an under-discussed 
phenomenon’ (2016) 36(5) Prenatal Diagnosis 391-396. 
 
5 
 
2.3 Post-test considerations 
 
Once parents have the test results they will need to interpret them.   They may need help to do 
this, both in terms of what the test results demonstrate and the potential implications for their 
future child.  There is strong support for post-test counselling,
21
 and in theory, there is 
nothing to prevent counselling being made available through online or telemedicine models.  
Indeed, there is some evidence that online decision making aids might be helpful for parents 
in the context of NIPT.
22
    
 
Once parents have interpreted the results, they might be faced with a difficult choice—
whether to continue with or terminate the pregnancy.  If they decide to continue, they may 
still want additional information and support.  If they decide to terminate the pregnancy, they 
have to consider what lawful options are available within their home country—not all States 
allow open-ended terminations and many impose time conditions and grounds.  This 
highlights another issue: testing for choices that are unlawful is confusing to parents and there 
is no guarantee of a coherent global narrative around testing and lawful choice.
23
   Of course, 
parents with sufficient means might consider travelling abroad to access treatment options not 
otherwise available at home.  This might create concerns and issues for both the home and 
foreign State—for the former because of the circumvention of domestic laws, and for the 
latter because of increased demand for (public) health services.
24
 We only need to look at 
Northern Ireland (which operates a stricter abortion regime compared to the rest of the UK) 
and the evidence of overseas travel to access abortion services not available at home.
25
 
 
Some parents might also look to e-commerce services and products (including abortifacients) 
not available at home following a positive test result.  This is turn may create issues around 
internet dispensing and concerns over the quality and safety of online medicines.
26
  Such 
services may also run counter to the local regulatory models—for example, in England a 
medical assessment is required in every case before it is lawful to supply drugs that are 
intended to procure an abortion.
27
   
 
                                                          
21
 Mercer (n 15) 989. 
 
22
 Lean Beulen et al., ‘The effect of a decision aid on informed decision-making in the era of non-invasive 
prenatal testing: a randomised controlled trial’ (2016) 24 Eur J of Human Genetics 1409. 
 
23
 For a domestic discussion, see Wale (n 10). 
 
24
 For discussion in the context of sex selection, see NCOB (n 5) at paras 4.47-4.48. 
 
25
 See for example the difficulties created around State funding in R (on the application of A) (A Child) (by her 
litigation friend B) v Secretary of State for Health UKSC 2015/0220.  
 
26
 LBS Clifton, ‘Internet Drug Sales: Is It Time to Welcome Big Brother into Your Medicine Cabinet’ (2004) 
20(2) Journal of Contemporary Health Law and Policy 541-570, at 554. 
 
27
 S59 Offences Against the Person Act 1861 and S1 Abortion Act 1967; Department of Health, Guidance in 
Relation to the Requirements of the Abortion Act 1967 (London: HMSO, 2014) at para 11. 
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2.4 Post-birth considerations 
Post-birth concerns extend to the continued security and management of personal data.  NIPT 
tests have the potential to capture a wide range of information including incidental findings 
about the mother and child.  The potential involvement of private and cross-border 
laboratories creates the opportunity for this information to be held in uncontrolled or semi-
controlled regulatory environments.  This in turn creates the risk of deliberate and accidental 
misuse and spread of data, which by its very nature is usually sensitive and deeply private.
28
   
We have outlined elsewhere
29
 a plausible basis for asserting a qualified right to know by the 
pregnant woman in relation to personal health information encompassing information about 
the developing fetus.  However, post-birth, should the child (X) have a right to know and 
access information held about his or her genetic profile, health or other personal 
characteristics?  What about X’s right to access incidental findings about his or her mother?  
And, what if X claims a right not to know? The questions for future generations, like the 
concerns, are extensive. 
3. Possible Responses 
How might regulators respond to the kinds of concerns that we have flagged up—not so 
much concerns about NIPT itself but about the availability and use of NIPT in the context of 
the global village? In this part of the paper, we start with some general remarks about the 
regulatory challenges before looking at responses to the concerns raised, specifically pre-test, 
post-test, and post-birth. 
3.1 Regulatory challenges in the global village 
Famously, in the early days of the Internet, the self-styled ‘cyberlibertarians’ maintained not 
only that online content should not be regulated but also that regulating it would prove 
impossible. Even if ‘impossible’ over-stated the degree of difficulty, early cases, such as 
LICRA v Yahoo! (2000),
30
 underlined the challenges facing regulators in one jurisdiction who 
seek to restrain the supply of online services that are hosted in another. Nevertheless, some 
responses might be feasible.
31
  
First, internet service providers, or other online intermediaries, might be prepared to act as 
‘chokepoints’, restricting supply of goods, services, or information from target sites.32 
                                                          
28
 Of course, there are already international instruments, such as the EU General Data Protection Regulation 
2016, that seek to address and co-ordinate State responses to the problem of personal data and privacy. 
 
29
 Roger Brownsword and Jeff Wale, 'The Development of Non-Invasive Prenatal Testing: Some Legal and 
Ethical Questions’ (2016) Band 24 Annual Review of Law and Ethics 31. 
 
30
  https://en.wikipedia.org/wiki/LICRA_v._Yahoo! (accessed 26/02/17). 
 
31
  Generally, see Roger Brownsword and Morag Goodwin, Law and the Technologies of the Twenty-First 
Century (Cambridge: Cambridge University Press, 2012) Ch 14. 
 
32
  Natasha Tusikov, Chokepoints: Global Private Regulation on the Internet (University of California Press, 
2016). 
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Secondly, it might be possible, as in the Yahoo case, for local regulators to target assets or 
personnel in the home jurisdiction. Thirdly, there might be opportunities for various kinds of 
reciprocal cross-border enforcement or other forms of cooperation between national 
regulators.
33
 That said, once local regulators seek to control Internet-based services that are 
hosted outside their jurisdiction, we have to lower our expectations about the effectiveness of 
interventions. 
3.2 Responding to pre-test concerns 
Responding to the principal pre-test concern—that the information given about, and around, 
NIPT will not be reliable and up-to-date—domestic regulators might adopt mandatory legal 
rules and guidelines that are applicable to all suppliers of NIPT services.
34
 These rules might 
provide for the licensing of NIPT with specific requirements relating to advertising, access 
and so on.
35
  There is a case for the renewable certification of websites and online forums 
supplying information about NIPT and related services.  This might include the use of 
certification logos (a symbol of a trustworthy source), perhaps indicating the date of last 
approval.
36
 The position might also be reinforced through ‘internet prescriptions’—where 
licensed medical practitioners are required to highlight ‘approved’ online sources of 
information and support about these tests.
37
    
Perhaps more controversially, if private provision creates an unacceptable regulatory risk, a 
State might respond by offering publicly funded tests.   Free access to NIPT testing would 
potentially squeeze the private sector (even without formal abolition) although this would 
depend on the degree of service equivalence.  Of course, as with the responses already 
indicated, this has significant resource implications that may prove unrealistic.
38
  Perhaps a 
more workable solution is some form of public/private partnership that utilises the proposed 
system of licensing,  certification and professional body regulation/guidance.
39 Ultimately, 
States must decide what is a ‘reasonable informational expectation’ in the context of 
                                                                                                                                                                                    
 
33
  See, e.g. Lawrence Lessig, Code Version 2.0 (New York: Basic Books, 2006) Ch 15. 
 
34
  See for example, the recent recommendations of the NCOB (n 5), chapter 6. 
 
35
 Although any rules would need to overcome existing international guidelines that licensing practices should 
not be used to restrict parental or healthcare providers’ choice (NCOB (n 5) at para 2.85). 
 
36
 Compare the mandatory EU internet logo and rules for online supply of medicines (see 
https://www.gov.uk/government/news/new-mandatory-logo-for-selling-medicines-online (accessed 23/02/17). 
 
37
 The importance of accurate, balanced and non-directive public sector sources of information about NIPT is 
recognised in the recent report by the NCOB (n 5) at para 6.27. 
 
38
 For discussion of the practical and financial difficulties of a publicly funded testing regime, see C Munthe, ‘A 
New Ethical Landscape of Prenatal Testing: Individualizing Choice to Serve Autonomy and Promote Public 
Health: A Radical Proposal’, (2015) 29(1) Bioethics 43. 
 
39
 The NCOB (n 5), Ch 6, envisages a combination of healthcare and disciplinary regulation and agreement with 
NIPT providers and manufacturers. 
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pregnancy,
40
 and then decide on the allocation of costs between the public and private 
sectors.  The public narrative is important and there should be some convergence between the 
aims of testing and any regulatory environment in which this information is processed and 
decisions made.
41
 
The blogosphere including parent based websites are harder to regulate.  Although freedom 
of expression might be legitimately restricted for the protection of health and morals,
42
 any 
State should be cautious about imposing restrictions where there is no evidence of fraud or 
malice on the part of users and operators.  To be sure, laws might be made to restrict or 
mandate online claims about the technology or that require support from peer reviewed 
sources where claims are made;
43
 but, it might be more productive to focus on addressing 
outdated or inaccurate claims by supporting those that engage productively through some 
form of approved certification process.
44
    
3.3 Responding to post-test concerns 
The principal post-test concerns relate to: (i) the range of results returned to pregnant women; 
(ii) the need for information and support to assist decision-making; and (iii) the purposes for 
which the test results might be applied. So, for example, the Nuffield Council on Bioethics 
has recently proposed: (i) that there should be strict domestic limits on the sweep of 
information to be returned;
45
 (ii) that mandatory parental support should be available from all 
providers;
46
 and (iii) that test providers should be prohibited from generating or reporting 
information about the sex of the fetus unless ‘there is concern that the fetus may be showing 
signs of a significant sex chromosome aneuploidy or is at risk of a sex-linked disorder.’47   
Beyond domestic regulation, co-operative global state engagement around the 
implementation of NIPT would be beneficial. There is the scope to develop guidelines around 
many of the issues discussed.
48
  Evidence of ‘healthcare tourism’ might be addressed through 
reciprocal international agreements that at least address the resource implications of this 
                                                          
40
 Z Deans, AJ Clarke and AJ Newson, ‘For Your Interest? The Ethical Acceptability of Using Non-invasive 
Prenatal Testing to Test “Purely for Information”’, (2015) 29 Bioethics 19-25 at 25. 
 
41
 For discussion, see Wale (n 10). 
 
42
 See for example, Art 10(2) of the European Convention on Human Rights. 
 
43
 Skirton (n 15); Mercer (n 15) 987; and ARC (n 18). 
 
44
 NCOB (n 5) para 6.39. 
 
45
 NCOB (n 5) paras. 6.4-6.18. 
 
46
 Ibid., para 6.40. 
 
47
 Ibid., para 6.16. 
 
48
 See, for e.g., Heather Skirton et al., ‘Offering prenatal diagnostic tests: European guidelines for clinical 
practice guidelines’, Eur J Hum Genet, (2014) 22(5) 580-6.  
(available at http://www.ncbi.nlm.nih.gov/pubmed/?term=24022298); and the proposed EU IVD Regulation 
(NCOB (n 5) at para 1.39). 
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behaviour.  However, recalling the caveats in 3.1, we cannot assume that all states will be 
willing reciprocators or co-operators. 
3.4 Responding to post-birth concerns 
If the post-birth concerns are to be addressed, there has to be a regulatory framework that (i) 
makes provision for the storage, security and future destruction of important personal data 
(including genetic data) and (ii) takes an acceptable position on the right to know and not to 
know. 
With regard to the former, there are obvious advantages in a coordinated global approach that 
encourages (if not requires through licence or other means) providers to be transparent about 
their processes for handling/storing data and the mechanisms for addressing any future areas 
of dispute.   Again, there might be some regulatory advantage in restricting or encouraging 
the use of services to jurisdictions that operate similar rules around data protection and 
privacy.  A default restriction on the use of NIPT data for any other purpose and a personal 
right to anonymity about the fact of testing might be appropriate (where not already 
available). 
With regard to the latter, while domestic regulators can consult with and then be guided by 
their community’s view of reasonable informational expectations, the positions taken are 
likely to differ from one state to another, this militating against global agreement. 
4. Conclusions 
In this short paper, we have focused on the development of a new form of genetic test, NIPT, 
in the context of the global Internet economy. Unlike some novel technologies, NIPT is not 
necessarily being piloted under carefully controlled conditions; rather it is being released at 
once into an environment that is particularly difficult to regulate.  
We have suggested that, over and above the reservations that some might have about NIPT, 
this raises several further concerns—particularly with regard to the reliability of the online 
information about NIPT, the possibility that women might use Internet suppliers to work 
round local legal restrictions, and the impact of stored genetic information on future children. 
While the global village is not easily regulated, we have suggested some responses that 
regulators might make to the aforementioned concerns. However, whatever we might make 
of these concerns, the reality is that, like other technologies relating to reproduction, NIPT 
will be exploited if women see a benefit and if commercial providers find a market for their 
services. 
